top of page


1 - Galceran J, Ameijide A, Carulla M, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799-825.

2 - Estimaciones de la incidencia del cáncer en España, 2019. Primeros resultados. Red Española de Registros de Cáncer (REDECAN), 2019.

3 - Hashibe M, Brennan P, Chuang SC et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers. Prev 2009;18:541–550.

4 - Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-1998.

5 - Ang KK, Harris J, Wheeler R et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med. 2010; 363:24–35.

6 - Coordes A, Lenz K, Qian X, et al. Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. Eur Arch Otorhinolaryngol 2016;273:2157-2169.

7 - Amin MB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer, 2017:XVII, 1024.

8 - de la Torre A, Romero J, Montero A, et al. Radiochemotherapy with cisplatin and oral tegafur in advanced head and neck cancer: long-term results of a phase II study. Tumori. 2008;94:453-8.

9 - Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005;27:175-181.

10 - Sheikhbahaei S, Taghipour M, Ahmad R, et al. Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and metaanalysis. AJR Am J Roentgenol 2015;205:629-639.

11 - de Martel C, Plummer M, Vignat J and Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 2017; 141:664–670

12 - Lassen P, Lacas B, Pignon JP et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol. 2018;126:107-115.

13 - Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group.. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.Radiother Oncol 2009;92:4–14.

14 - Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33–40.

15 - Denis F, Garaud P, Bardet E, et al.. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69–76.

16 - Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006; 354:567-578

17 - Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals of Oncology 2014;25:216–225.

1813 - Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257–64

19 - Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. J Clin Oncol 2014;32:2735-2743.

20 - Mo HL, Li J, Yang X et al. Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and meta-analysis. Lasers Med Sci. 2017;32:461-467.

21 - Yamazaki H, Nishiyama K, Tanaka E et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006;64:77-82.

22 - Kodaira T, Kagami Y, Shibata T et al. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701). Annals of Oncology, 2018;29:992–997.

23 - Moon SH, Cho KH, Chung EJ et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol. 2014;110:98-103.

24 - Chaudhary N, Verma RK, Agarwal U, Gupta S, Jaitly S. Incidence of occult metastasis in clinically N0 oral tongue squamous cell carcinoma and its association with tumor staging, thickness, and differentiation. J Head Neck Physicians Surg 2017;5:75-8.

25 - S. Córdoba, J. Romero, F. Valcárcel et al. Observación frente a tratamiento electivo en cáncer de lengua móvil con cuello clínicamente negativo: resultados de una serie de 243 pacientes.Oncología 27(1):13-20; 2004.

26 - Ho CM, Lam KH, Wei W and Lam LK. Occult lymph node metastasis in small oral tongue cancers. Head Neck 1992;14:359-363

27 - Giammarile F, Schilling C, Gnanasegaran G, et al. The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:623-637.

28 - Zhanga H, Seikalyb H, Bironb VL, Jefferyb CC. Utility of PET-CT in detecting nodal metastasis in cN0 early stage oral cavity squamous cell carcinoma. Oral Oncology 2018;80:89–92

29 - Schilling C, Stoeckli SJ, Haerle SK, et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. European Journal of Cancer 2015;51:2777-2784

30 - Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.

31 - Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.

32 - Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.

33 - Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84:1198-205.

34 - Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015;136:E359–E386

36 - El-Naggar A, Chan J, Grandis J, et al. WHO classification of head and neck tumours. Lyon, France: IARC Press, 2017.

37 - Ng SH, Chang TC, Ko SF, et al. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 1997;39:741–746.

38 - Perez CA, Devineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23(2):271–280.

39 - Lee AW, Chan DK, Fowler JF, et al. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol 1995;36:24–31.

40 - Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.

40 - Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-53

41 - Blanchard P, Lee A, Marguet S, et al.Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645-55.

42 - Chajón EA, García-Berrocal MI, De la Fuente C, Regueiro C, Romero J, Valcárcel F. Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: a single institution experience using the Intergroup 0099 study regimen. Acta Oncol. 44(1):85-86, 2005

43 - Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-171

44 - Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509-1520.

45 - Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrentadjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 2015;121:1328-1338.

Wei2005 - Wei WI and Sham JST. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041–54

bottom of page